Published in Physician Law Weekly, August 29th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Medtronic, Inc.
Report 1: Medtronic, Inc. (NYSE:MDT), announced the completion of implants in its U.S. pivotal clinical study of deep brain stimulation (DBS) for the treatment of medically refractory epilepsy, a form of the neurological condition that does not respond to antiepileptic drugs. With 110 patients now implanted with the Intercept(TM) Epilepsy Control System, results of the study - the SANTE (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy) Trial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.